(SYK) Stryker - Overview
Stock: Implants, Instruments, Navigation, Endoscopy, Orthobiologics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.92% |
| Yield on Cost 5y | 1.48% |
| Yield CAGR 5y | 7.09% |
| Payout Consistency | 95.3% |
| Payout Ratio | 29.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.0% |
| Relative Tail Risk | -5.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.49 |
| Alpha | -21.27 |
| Character TTM | |
|---|---|
| Beta | 0.673 |
| Beta Downside | 0.714 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.56% |
| CAGR/Max DD | 0.72 |
Description: SYK Stryker January 27, 2026
Stryker Corporation (NYSE: SYK) is a U.S.-based medical-technology firm founded in 1941 and headquartered in Portage, Michigan. It sells its products in roughly 75 countries through a mix of direct subsidiaries and third-party distributors, targeting doctors, hospitals, and other healthcare facilities.
The company operates two primary segments. The MedSurg & Neurotechnology segment delivers a broad portfolio that includes surgical equipment, navigation and communication systems, AI-enabled virtual-care platforms, acute-stroke minimally invasive devices, cranial and maxillofacial products, dural substitutes, and orthobiologic solutions such as synthetic bone grafts. The Orthopaedics segment focuses on implants for total joint replacements (hip, knee, shoulder), trauma and extremities, as well as thoracolumbar spinal fixation and minimally invasive interbody systems.
In FY 2025 Stryker reported $17.1 billion in revenue, a 6 % year-over-year increase driven by strong demand for joint-replacement implants and growth in its AI-assisted surgical platforms; operating margin expanded to 19 % and free cash flow reached $2.3 billion. Key sector drivers include an aging U.S. population (projected to reach 77 million over 65 by 2030) and accelerating hospital adoption of digital-surgery tools, both of which underpin Stryker’s growth outlook. For a deeper, data-rich analysis of how these trends translate into valuation dynamics, a quick look at ValueRay’s platform may be worthwhile.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 3.25b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.84 > 1.0 |
| NWC/Revenue: 27.72% < 20% (prev 32.00%; Δ -4.29% < -1%) |
| CFO/TA 0.11 > 3% & CFO 5.04b > Net Income 3.25b |
| Net Debt (10.85b) to EBITDA (5.58b): 1.94 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (386.5m) vs 12m ago 0.10% < -2% |
| Gross Margin: 63.54% > 18% (prev 0.62%; Δ 6293 % > 0.5%) |
| Asset Turnover: 55.31% > 50% (prev 52.58%; Δ 2.73% > 0%) |
| Interest Coverage Ratio: 14.24 > 6 (EBITDA TTM 5.58b / Interest Expense TTM 316.0m) |
Altman Z'' 3.91
| A: 0.15 (Total Current Assets 14.76b - Total Current Liabilities 7.79b) / Total Assets 47.84b |
| B: 0.42 (Retained Earnings 19.96b / Total Assets 47.84b) |
| C: 0.10 (EBIT TTM 4.50b / Avg Total Assets 45.41b) |
| D: 0.88 (Book Value of Equity 22.42b / Total Liabilities 25.42b) |
| Altman-Z'' Score: 3.91 = AA |
Beneish M -3.04
| DSRI: 0.91 (Receivables 4.04b/3.99b, Revenue 25.12b/22.59b) |
| GMI: 0.97 (GM 63.54% / 61.52%) |
| AQI: 1.09 (AQ_t 0.61 / AQ_t-1 0.56) |
| SGI: 1.11 (Revenue 25.12b / 22.59b) |
| TATA: -0.04 (NI 3.25b - CFO 5.04b) / TA 47.84b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of SYK shares?
Over the past week, the price has changed by -3.05%, over one month by -2.21%, over three months by +1.52% and over the past year by -8.70%.
Is SYK a buy, sell or hold?
- StrongBuy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the SYK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 424.4 | 18.5% |
| Analysts Target Price | 424.4 | 18.5% |
| ValueRay Target Price | 389.1 | 8.6% |
SYK Fundamental Data Overview February 07, 2026
P/E Forward = 24.0964
P/S = 5.5183
P/B = 6.1519
P/EG = 1.478
Revenue TTM = 25.12b USD
EBIT TTM = 4.50b USD
EBITDA TTM = 5.58b USD
Long Term Debt = 14.86b USD (from longTermDebt, last quarter)
Short Term Debt = 14.86b USD (from shortTermDebt, last quarter)
Debt = 14.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.85b USD (from netDebt column, last quarter)
Enterprise Value = 149.45b USD (138.60b + Debt 14.86b - CCE 4.01b)
Interest Coverage Ratio = 14.24 (Ebit TTM 4.50b / Interest Expense TTM 316.0m)
EV/FCF = 34.89x (Enterprise Value 149.45b / FCF TTM 4.28b)
FCF Yield = 2.87% (FCF TTM 4.28b / Enterprise Value 149.45b)
FCF Margin = 17.05% (FCF TTM 4.28b / Revenue TTM 25.12b)
Net Margin = 12.92% (Net Income TTM 3.25b / Revenue TTM 25.12b)
Gross Margin = 63.54% ((Revenue TTM 25.12b - Cost of Revenue TTM 9.16b) / Revenue TTM)
Gross Margin QoQ = 65.22% (prev 63.60%)
Tobins Q-Ratio = 3.12 (Enterprise Value 149.45b / Total Assets 47.84b)
Interest Expense / Debt = 1.06% (Interest Expense 157.0m / Debt 14.86b)
Taxrate = 28.09% (1.27b / 4.51b)
NOPAT = 3.24b (EBIT 4.50b * (1 - 28.09%))
Current Ratio = 1.89 (Total Current Assets 14.76b / Total Current Liabilities 7.79b)
Debt / Equity = 0.66 (Debt 14.86b / totalStockholderEquity, last quarter 22.42b)
Debt / EBITDA = 1.94 (Net Debt 10.85b / EBITDA 5.58b)
Debt / FCF = 2.53 (Net Debt 10.85b / FCF TTM 4.28b)
Total Stockholder Equity = 21.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.15% (Net Income 3.25b / Total Assets 47.84b)
RoE = 15.04% (Net Income TTM 3.25b / Total Stockholder Equity 21.58b)
RoCE = 12.35% (EBIT 4.50b / Capital Employed (Equity 21.58b + L.T.Debt 14.86b))
RoIC = 8.52% (NOPAT 3.24b / Invested Capital 37.95b)
WACC = 7.66% (E(138.60b)/V(153.46b) * Re(8.40%) + D(14.86b)/V(153.46b) * Rd(1.06%) * (1-Tc(0.28)))
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF Debug] Terminal Value 82.37% ; FCFF base≈3.96b ; Y1≈4.89b ; Y5≈8.33b
Fair Price DCF = 366.6 (EV 151.06b - Net Debt 10.85b = Equity 140.21b / Shares 382.4m; r=7.66% [WACC]; 5y FCF grow 24.98% → 2.90% )
EPS Correlation: 37.23 | EPS CAGR: 24.42% | SUE: 0.25 | # QB: 0
Revenue Correlation: 92.23 | Revenue CAGR: 14.79% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=3.00 | Chg30d=-0.071 | Revisions Net=-8 | Analysts=25
EPS current Year (2026-12-31): EPS=14.97 | Chg30d=+0.022 | Revisions Net=+8 | Growth EPS=+9.8% | Growth Revenue=+8.7%
EPS next Year (2027-12-31): EPS=16.73 | Chg30d=+0.014 | Revisions Net=+7 | Growth EPS=+11.8% | Growth Revenue=+8.4%